Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Revenue (2022 - 2025)

Dianthus Therapeutics has reported Revenue over the past 4 years, most recently at $396000.0 for Q3 2025.

  • Quarterly results put Revenue at $396000.0 for Q3 2025, down 81.77% from a year ago — trailing twelve months through Sep 2025 was $3.1 million (down 42.64% YoY), and the annual figure for FY2024 was $6.2 million, up 120.63%.
  • Revenue for Q3 2025 was $396000.0 at Dianthus Therapeutics, up from $193000.0 in the prior quarter.
  • Over the last five years, Revenue for DNTH hit a ceiling of $5.2 million in Q3 2022 and a floor of $193000.0 in Q2 2025.
  • Median Revenue over the past 4 years was $969000.0 (2023), compared with a mean of $1.3 million.
  • Biggest five-year swings in Revenue: surged 190.15% in 2024 and later plummeted 89.64% in 2025.
  • Dianthus Therapeutics' Revenue stood at $1.2 million in 2022, then crashed by 60.54% to $457000.0 in 2023, then skyrocketed by 190.15% to $1.3 million in 2024, then crashed by 70.14% to $396000.0 in 2025.
  • The last three reported values for Revenue were $396000.0 (Q3 2025), $193000.0 (Q2 2025), and $1.2 million (Q1 2025) per Business Quant data.